AstraZeneca Acquires Modella AI

AstraZeneca to Acquire EsoBiotec

March 18, 2025

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company developing in vivo cell therapies. The deal is valued at up to $1 billion on a cash and debt-free basis, with an initial $425 million payment upon closing plus up to $575 million in contingent milestone consideration. The transaction is expected to close in Q2 2025, subject to regulatory approvals.

AstraZeneca (Alexion) Acquires Amolyt Pharma for Up to $1.05 Billion

March 14, 2024

Biotechnology

Amolyt Pharma, a clinical-stage biotech focused on rare endocrine diseases, entered into a definitive agreement to be acquired by AstraZeneca’s Rare Disease business (Alexion) for $800 million upfront plus up to $250 million in regulatory milestone contingent payments. The total deal value is up to $1.05 billion and is expected to close by the end of Q3 2024, subject to customary closing conditions and regulatory clearances.

AstraZeneca Acquires Fusion Pharmaceuticals

March 19, 2024

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage company developing next-generation actinium-based radioconjugates, for $21.00 per share in cash plus a non-transferable contingent value right that could bring the total to approximately $2.4 billion. The acquisition adds Fusion's pipeline (including FPI-2265 for mCRPC), R&D and manufacturing capabilities in radioconjugates and strengthens AstraZeneca's oncology portfolio and presence in Canada.

Aktana Acquires Ople.AI's Machine Learning Automation Technology

October 27, 2021

AI & Machine Learning

Aktana has acquired Ople.AI's machine learning automation technology to integrate into its Contextual Intelligence 360 platform, enabling non-data scientists at life sciences companies to build and deploy ML models more easily. The acquisition is intended to democratize AI across commercial life sciences teams and accelerate AI adoption by simplifying model creation, deployment and transparent explanations.

StarLIMS to Acquire Lonza’s MODA Platform

March 25, 2026

Cloud & SaaS

StarLIMS has agreed to acquire the MODA Platform from Lonza, expanding deeper into manufacturing operations and quality control in regulated environments. The transaction is expected to close in Q2 2026, subject to customary closing conditions, and will extend StarLIMS’ LIMS offering into manufacturing workflows via an end-to-end lab-to-floor solution.

ZS Acquires Trials.ai to Add AI-Driven Study Design

February 6, 2023

AI & Machine Learning

Global consulting and technology firm ZS has entered into a definitive agreement to acquire Trials.ai, an AI-powered clinical study design company. The acquisition will integrate Trials.ai's intelligent study-design capabilities into ZS's clinical development offerings to help sponsors identify risks, optimize participant experience and accelerate therapy development timelines.